Neuroimmunophilin ligands in the treatment of Parkinson's disease.
Parkinson's disease treatments can be divided into three categories: symptomatic, protective and restorative. This review focuses on the restorative and neuroprotective actions of a new class of potential therapeutic agents, neuroimmunophilin ligands. To date, however, short-term treatments with two such compounds in a non-human primate model and in patients with Parkinson's disease have been disappointing.
Gold
Bruce G
BG
Center for Research on Occupational and Environmental Toxicology, Department of Cell and Developmental Biology, Oregon Health & Science University, Portland, OR 97201-3098, USA. gold@ohsu.edu
Nutt
John G
JG
D000818:Animals; D006801:Humans; D020104:Immunophilins / Q000378:metabolism* / Q000627:therapeutic use*; D008024:Ligands; D009474:Neurons / Q000637:transplantation; D010300:Parkinson Disease / Q000188:drug therapy* / Q000601:surgery
D008024:Ligands; D020104:Immunophilins